Michael L. Johnson

19.6k total citations · 2 hit papers
352 papers, 14.8k citations indexed

About

Michael L. Johnson is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Psychiatry and Mental health. According to data from OpenAlex, Michael L. Johnson has authored 352 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Cardiology and Cardiovascular Medicine, 56 papers in Endocrinology, Diabetes and Metabolism and 42 papers in Psychiatry and Mental health. Recurrent topics in Michael L. Johnson's work include Pharmaceutical Practices and Patient Outcomes (40 papers), Growth Hormone and Insulin-like Growth Factors (39 papers) and Hypothalamic control of reproductive hormones (35 papers). Michael L. Johnson is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (40 papers), Growth Hormone and Insulin-like Growth Factors (39 papers) and Hypothalamic control of reproductive hormones (35 papers). Michael L. Johnson collaborates with scholars based in United States, Canada and United Kingdom. Michael L. Johnson's co-authors include Johannes D. Veldhuis, J. D. Veldhuis, Ali Iranmanesh, Michael O. Thorner, GERMAN LIZARRALDE, Fred Kern, Alan D. Rogol, Rajender R. Aparasu, William S. Evans and D Z Braverman and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael L. Johnson

342 papers receiving 14.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cluster analysis: a simple, versatile, and robust algorithm for endocrine pulse detection

1986 807 citations Michael L. Johnson et al. profile →
The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations.

1987 473 citations Michael L. Johnson et al. profile →

Peers

Countries citing papers authored by Michael L. Johnson

Since Specialization

Citations

This map shows the geographic impact of Michael L. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Johnson more than expected).

Fields of papers citing papers by Michael L. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Johnson. The network helps show where Michael L. Johnson may publish in the future.

Co-authorship network of co-authors of Michael L. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Johnson. A scholar is included among the top collaborators of Michael L. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Johnson. Michael L. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer’s Disease Initiating Cholinesterase Inhibitors 2024 ·Drugs & Aging ·(unknown), Satabdi Chatterjee, Jeffrey T. Sherer, Susan Abughosh, Michael L. Johnson, Rajender R. Aparasu	1
2	Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer 2024 ·Cancers ·RK Goyal, Sean D. Candrilli, Susan Abughosh, Hua Chen, Holly M. Holmes, Michael L. Johnson	1
3	Trajectories of adherence to ACEI/ARB medications following a motivational interviewing intervention among Medicare Advantage beneficiaries in Texas 2023 ·Patient Education and Counseling ·(unknown), (unknown), (unknown), Michael L. Johnson, Ekere James Essien, Susan Abughosh	4
4	A Motivational Interviewing Intervention to Improve Adherence to ACEIs/ARBs among Nonadherent Older Adults with Comorbid Hypertension and Diabetes 2023 ·Drugs & Aging ·(unknown), (unknown), Michael L. Johnson, Ekere James Essien, Jamie C. Barner, Omar Serna, (unknown), Marc L. Fleming, (unknown), Marcia McDonnell Holstad, Susan Abughosh	15
5	Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis 2023 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), (unknown), George J. Hutton, Michael L. Johnson, Rajender R. Aparasu	1
6	Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study 2023 ·Clinical Therapeutics ·Yinan Huang, Sandeep K. Agarwal, Hua Chen, Satabdi Chatterjee, Michael L. Johnson, Rajender R. Aparasu	2
7	Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study 2023 ·Clinical Rheumatology ·Yinan Huang, Sandeep K. Agarwal, Satabdi Chatterjee, Hua Chen, Michael L. Johnson, Rajender R. Aparasu	2
8	Parent psychosocial adjustment to inpatient pediatric rehabilitation, and the role of uncertainty and self-care. 2023 ·Rehabilitation Psychology ·Dana M. Bakula, (unknown), (unknown), (unknown), Christina Sharkey, Hannah C. Espeleta, (unknown), (unknown), Michael L. Johnson, (unknown), Larry L. Mullins	1
9	Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study 2022 ·Drugs & Aging ·(unknown), Satabdi Chatterjee, Jeffrey T. Sherer, Hua Chen, Michael L. Johnson, Rajender R. Aparasu	6
10	Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study 2021 ·Drugs & Aging ·Sanika Rege, Ryan M. Carnahan, Michael L. Johnson, Hua Chen, Holly M. Holmes, Rajender R. Aparasu	3
11	Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis 2021 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), George J. Hutton, J. Douglas Thornton, Hua Chen, Michael L. Johnson, Rajender R. Aparasu	2
12	Risk of overactive bladder associated with cholinesterase inhibitors in dementia 2021 ·Journal of the American Geriatrics Society ·(unknown), Satabdi Chatterjee, Jeffrey T. Sherer, Hua Chen, Michael L. Johnson, Rajender R. Aparasu	3
13	<p>Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression</p> 2020 ·Drug Healthcare and Patient Safety ·(unknown), Holly M. Holmes, Michael L. Johnson, Hua Chen, Jeffrey T. Sherer, Rajender R. Aparasu	8
14	Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study 2020 ·Journal of General Internal Medicine ·(unknown), Holly M. Holmes, Michael L. Johnson, Hua Chen, Rajender R. Aparasu	11
15	Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder 2020 ·International Journal of Geriatric Psychiatry ·(unknown), Holly M. Holmes, Michael L. Johnson, Hua Chen, Rajender R. Aparasu	6
16	<p>Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis</p> 2020 ·Patient Preference and Adherence ·(unknown), George J. Hutton, J. Douglas Thornton, Hua Chen, Michael L. Johnson, Rajender R. Aparasu	12
17	Effect of Phenology on Total Available Carbohydrates and Crude Protein in Tobosagrass 2016 ·James T. Nelson, Michael L. Johnson	0
18	VHA pharmacy use in veterans with Medicare drug coverage. 2009 ·PubMed ·Robert O. Morgan, Laura A. Petersen, (unknown), Jessica A. Davila, (unknown), (unknown), (unknown), Michael L. Johnson	41
19	Network-Centric Operations Case Study: The Stryker Brigade Combat Team 2005 ·Defense Technical Information Center (DTIC) ·(unknown), Michael L. Johnson, (unknown), (unknown), (unknown), (unknown)	7
20	Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. 2004 ·PubMed ·Michael L. Johnson, Kenneth Pietz, David Battleman, Rebecca J. Beyth	100

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact